Shares of Teleflex Incorporated (NYSE:TFX) have earned a consensus recommendation of “Buy” from the ten analysts that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $324.86.
A number of research analysts have commented on TFX shares. Needham & Company LLC restated a “strong-buy” rating and set a $325.00 price target (up from $300.00) on shares of Teleflex in a research note on Friday, February 22nd. Barclays set a $287.00 price target on Teleflex and gave the stock a “hold” rating in a research note on Friday, February 22nd. Morgan Stanley upped their price target on Teleflex from $305.00 to $315.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 26th. Zacks Investment Research upgraded Teleflex from a “hold” rating to a “buy” rating and set a $338.00 price target on the stock in a research note on Friday, May 10th. Finally, Raymond James upped their price target on Teleflex from $320.00 to $348.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, March 27th.
In other Teleflex news, VP Cameron P. Hicks sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $288.00, for a total transaction of $576,000.00. Following the transaction, the vice president now owns 4,696 shares of the company’s stock, valued at $1,352,448. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Stuart A. Randle sold 4,000 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $290.52, for a total value of $1,162,080.00. Following the transaction, the director now directly owns 7,421 shares in the company, valued at approximately $2,155,948.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,376 shares of company stock worth $11,381,818. 2.36% of the stock is owned by insiders.
NYSE:TFX opened at $295.60 on Thursday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.41 and a current ratio of 2.27. Teleflex has a 52 week low of $226.02 and a 52 week high of $309.99. The firm has a market cap of $13.57 billion, a price-to-earnings ratio of 29.86, a PEG ratio of 1.97 and a beta of 1.01.
Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, May 2nd. The medical technology company reported $2.24 EPS for the quarter, topping analysts’ consensus estimates of $2.17 by $0.07. Teleflex had a return on equity of 18.62% and a net margin of 7.50%. The company had revenue of $613.60 million for the quarter, compared to analysts’ expectations of $608.27 million. During the same period in the prior year, the firm earned $2.15 earnings per share. The firm’s revenue was up 4.5% compared to the same quarter last year. As a group, analysts anticipate that Teleflex will post 11.05 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Wednesday, May 15th will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend is Tuesday, May 14th. Teleflex’s dividend payout ratio is presently 13.74%.
Teleflex Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Further Reading: How to trade on quiet period expirations
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.